Medical devices, healthcare technology and the business of care
510(k) clearance · K260566

SMARTVERTIGO Vestibular Assessment System

VertigoDx, Inc. · Decision date Jul 30, 2026

FDA DECISIONK260566

What did the FDA decide?

FDA records K260566 as a 510(k) premarket notification, with a decision dated Jul 30, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Neurology
Decision date
Jul 30, 2026

FDA source record

Regulatory record facts

Identifier
K260566
Regulatory pathway
510(k) premarket notification
Product code
GWN
Decision code
SESE
Decision date
Jul 30, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Nystagmograph.

Product code
GWN
FDA device class
2

FDA decision timeline

  1. K260566 received

    Application receipt date recorded by FDA.

  2. K260566 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

VertigoDx, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Wilmington, DE

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records